杰成(cheng)醫療(健(jian)適醫療成(cheng)員企業)的"經血(xue)管(guan)介(jie)入(ru)生物(wu)主(zhu)動(dong)(dong)脈瓣(ban)(ban)膜(mo)"在國內(nei)首次(ci)得(de)到成(cheng)功(gong)應(ying)用(yong)，兩(liang)名心臟瓣(ban)(ban)膜(mo)病患者(zhe)通(tong)過經導管(guan)主(zhu)動(dong)(dong)脈瓣(ban)(ban)置換術(TAVR)各被植(zhi)入(ru)一枚(mei)"杰成(cheng)經血(xue)管(guan)介(jie)入(ru)瓣(ban)(ban)膜(mo)"。杰成(cheng)醫療已計劃對(dui)該產(chan)品(pin)在全球范圍內(nei)開展多(duo)個前瞻性多(duo)中心注(zhu)冊臨床(chuang)研究，這是該產(chan)品(pin)的首次(ci)臨床(chuang)試驗，后(hou)續即將在美國啟動(dong)(dong)臨床(chuang)試驗。(醫藥健(jian)聞(wen))